LDS/Medical Tests/Hereditary Angioedema Diagnostic Panel

Hereditary Angioedema Diagnostic Panel

Hereditary Angioedema (HAE) is a rare and potentially life-threatening genetic condition that occurs in only 1 in 10,000 to 1 in 50,000 people. This is an autosomal dominant disorder and HAE patients have a defect in the gene that controls a blood protein, C1-esterase inhibitor. This gene is the C1-INH gene, also known as the SERPING1 gene. This genetic defect results in the production of either inadequate or non-functioning C1-inhibitor protein. This means that the defective gene produces a C1-esterase inhibitor protein that either does not function the way it should or that the quantitative amount of C1-inhibitor protein produced is less than normal and inadequate to inhibit C1-esterase.

About 85% of patients have a mutation that results in inadequate levels of C1-esterase inhibitor (Type I), and the remaining 15% have a mutation leading to a non-functional inhibitor (Type II). The result of either mutation is that the first component of the complement cascade, C1, is activated inappropriately and itself activates the next component, C2. Activated C2 releases a peptide (short protein) with kinin activity that increases the permeability (“leakiness”) of blood vessels. This will result in fluid accumulation (edema) in the soft tissues of the body, including the gastrointestinal tract, upper respiratory tract (including the larynx) and subcutaneous tissue of the skin.  

Patients can experience excruciating abdominal pain, nausea, and vomiting that is due to the swelling of the intestinal wall. Swelling of the larynx (upper airway) can be lethal due to death by asphyxiation. HAE is termed a hereditary condition, which means that this condition can be passed from one generation to the next and so on. The chance of a child obtaining this defect from a parent with one defective gene is 50%. Consequently, these patients can pass the defective gene to their offspring. However, about 50% of patients classified as having HAE have no family history of angioedema. These cases are thought to occur due to a spontaneous mutation at conception. There is a third type of HAE, type III, which is associated with mutations of the F12 gene that produces the coagulation factor XII.

Since this condition is rare, it is not uncommon for patients to remain undiagnosed for many years. Most attacks occur spontaneously with no apparent cause; however, they can be triggered by anxiety, stress, minor trauma, surgery, and illnesses such as a cold or the flu. Trauma to the oral cavity caused by dental procedures make HAE patients particularly vulnerable to airway attacks. Also, various physical activities have been known to trigger these attacks such as lawn mowing, shoveling, and other types of physical activities. In women, menstruation and pregnancy seem to have a major effect on disease activity. HAE is not restricted to any specific age group. Patients often report a tingling or tightness at the site where edema will occur approximately 30 minutes to several hours later. Approximately one fourth of HAE patients experience a flat, non-itching red blotchy rash both before and during an attack.

Measurement of serum C1q antigen is crucial to the categorization of angioedema.  Patients with normal C1q levels have the hereditary form (HAE) and those with low C1q levels have the acquired form. The acquired form is associated with several diseases including hematologic malignancies such as lymphoma, multiple myeloma and others.

To distinguish type I from type II HAE, the C1-inhibitor quantitative (antigenic) and C1-inhibitor functional assays can be performed. In addition, complement 4 (C4) level can be obtained to confirm activation of the complement cascade. C1-INH deficiency accounts for a small percentage of angioedema cases, so it is vital that laboratory testing be done to avoid the serious consequences and possibly unnecessary surgery.

  • C1-INH antigen assay and C1-INH functional assay should be performed in order to:
  • Diagnose Hereditary Angioedema
  • To determine type 1 versus type 2 HAE
  • To distinguish HAE from other etiologies of angioedema
  • To monitor replacement therapy in HAE C1-INH (SERPING 1) gene mutation:
  • To diagnose Heritary angioedema types I and II
  • To distinguish Hereditary from acquired angioedema
  • Therapy monitoring and disease management F12 gene mutation:
  • Confirmatory diagnosis of Hereditary angioedema type III C1q level:
  • Differential diagnosis of  Hereditary from Acquired angioedema C4 level:
  • To determine if the complement cascade has been activated. This is the best screening test for angioedema, since either hereditary or acquired will show a low level during and sometimes even before an attack.
  • HAE-type 1:  Decreased C1-inhibitor quantity and C4. C1q level normal.
  • HAE-type 2:  C1-inhibitor quantity normal but protein is dysfunctional. C4 is decreased. C1q level normal.
  • HAE-type III:
  • AAE-1: Decreased C1-inhibitor and C4. C1q may be decreased
  • AAE-2: same as AAE-1.

C1-INH (SERPING 1):  Not mutated

F12 gene: Not mutated

C1 Esterase Inhibitor antigen: 19 – 37 mg/dL

C1 Esterase Inhibitor Functional assay:

>67% of normal is Normal

41 – 67% of normal is Equivocal

<41% of normal is Abnormal

Molecular (PCR/ARMS, sequencing), Immunoassay, Semi-quantitative ELISA, Rate nephelometry, radial immunodiffusion, and turbidity.

Whole blood in EDTA (lavender) tube (for molecular genetic testing). 

Stability

  • Ambient: 3-5 days
  • Refrigerated: 5-7 days
  • Frozen: 30 days
C1, C3, C4, C1q, and C1 esterase inhibitor. C1-INH (SERPING1) gene mutation by sequencing.
5-10 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Clin Immunol. 2005 Jan;114(1):3-9. [PMID: 15596403]
  • Curr Opin Hematol. 2005 Nov;12(6):493-8. [PMID: 16217168]
  • J Clin Pathology. 2004 Feb;57(2):213-4. [PMID: 14747456]
  • Blood. 1997 May; 89(9): 3213-8. [PMID: 9129025]
  • Dreskin SC, Urticaria and angioedemia. In: Goldman L, Schafer Al (eds.) Cecil Medicine. 24th ed. Philadelphia, PA: Saunders Elsevier; 2011: chap 260.
  • Wasserman SI. Approach to the person with allergic or immunologic disease. In: Goldman L, Schafer Al (eds.) Cecil Medicine. 24th ed. Philadelphia, PA: Saunders Elsevier; 2011: chap 257.